Alira Health’s Ventures Portfolio Company, X-COR Therapeutics, Closes Initial $2.6M Funding Round

X-COR’s innovative technology transforms support for patients with respiratory failure and includes COVID-19 treatment applications.

News
Published on:
November 20, 2020

FRAMINGHAM, MASSACHUSETTS – November 12, 2020 – Alira Health (www.alirahealth.com), a leading international healthcare and life sciences advisory firm, congratulates X-COR Therapeutics for closing a $2.6M seed financing to continue developing its novel extracorporeal carbon dioxide removal device for use in clinical trials. Alira Health’s investment arm, Alira Health Ventures, added X-COR Therapeutics in 2019 as a portfolio company and led the recent seed financing with syndication from Good Growth Capital, PiSA Biopharm, Flybridge Partners’ Graduate Syndicate, and other notable angel investors.

“X-COR Therapeutics is continuing to develop its novel filtration system and compatible dialysate strategy for clinical testing and regulatory assessment. Working with the Alira Health Ventures Team generated additional momentum for X-COR to advance development during the COVID-19 pandemic and the addition of Gabriele Brambilla to our board further accelerates our progress,” said Jayon Wang, CEO of X-COR.

“We are pleased with the X-COR Team’s progress through this unprecedented year and are proud to work with such an elite investor group supporting this important technology,” said Gabriele Brambilla, Alira Health’s CEO. “Alira Health Ventures is dedicated to nurturing innovative technologies and propelling development from concept to clinical evaluation for future commercialization. X-COR’s technology will be transformational in the lives of patients suffering from respiratory failure, and this funding is a key milestone in accelerating the development of this vital technology.”

About X-COR Therapeutics:

X-COR Therapeutics is a Boston-based medical device company creating the first commercially available carbon dioxide removal device that uses ultra-low-blood flows for a cheaper, safer, and more accessible treatment for acute respiratory failure. X-COR’s novel technology is a patent-pending medical device and accompanying control algorithm that enables physicians to directly remove excess carbon dioxide from lung failure patients.
To learn more about X-COR, visit http://xcortherapeutics.com/

About Alira Health Ventures:

As part of Alira Health, Alira Health Ventures is an accelerator for an innovative group of portfolio companies positioned to launch the next breakthrough technologies in medical devices and pharmaceuticals. From discovery to commercialization, Alira Health Ventures invests in products that advance healthcare and impact patients’ lives.

Read the press release on Businesswire here.

For more information about Alira Health Ventures

Click here

Related news

Regulatory
News February 2, 2021
We Secured Breakthrough Device Designation from FDA on PEDRA Xauron Perfusion System
We are proud to announce the firm’s Regulatory practice has secured a Breakthrough Device Designation from FDA for the real-time tissue perfusion system, PEDRA Xauron Perfusion System.
Clinical Regulatory
News January 7, 2021
Alira Health Adds CMC Services through Acquisition of Chamow & Associates
We have acquired Chamow & Associates (www.chamowassociates.com), a California-based integrated CMC advisory firm. This acquisition brings expertise in biologics manufacturing, quality(...)
Advanced Analytics
News December 1, 2020
We Achieved AWS Select Consulting Partner Status
We have recently earned Amazon Web Services (AWS) Select Consulting Partner status. The firm’s newly formed Advanced Analytics practice will leverage AWS’s cloud computing capabilities(...)
Regulatory
Publications November 1, 2020
Reduce Time to Market with Pre-IND Meetings
Did you know reducing time to market is one of the biggest challenges companies face when seeking FDA approval on their drug development plans and clinical trials?
Advanced Analytics Market Access Pharma
Publications November 1, 2020
Our Parallel Trade Expertise
Alira Health is proud to announce our new collaboration with Mark Inigo Jones, an industry leader in European parallel trade of pharmaceutical products.
Advanced Analytics
News October 28, 2020
Together with Embleema we Announce Partnership to Deploy Next-Generation Real-World Data Solutions for Life Sciences
This strategic partnership brings next-generation real-world data solutions to the healthcare industry, improving patient outcomes through rich, continuous data, and regulatory-grade evidence.
Advanced Analytics
Publications October 13, 2020
Developing Learning Organizations around Health Data
Alira Health, a healthcare and life sciences consultancy with expertise in health data, approaches the development of health data in an integrated way, bringing together clinicians,(...)

Our locations around the globe

Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.